Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the Third Annual Next-Gen Immuno-oncology Congress occurring virtually June 25-26, 2020.

John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will present "Targeting Bispecific Antibodies and Developing Systems Disease Models in Immuno-oncology" Thursday, June 25th at 12:55 p.m. US EST. In this presentation, Dr. Burke will highlight mathematical modeling efforts that have de-risked projects, accelerated the discovery and development of best-in-class therapeutics, and impacted critical decisions or provided deep biological insights in the continuum from preclinical exploration to clinical research. Examples will include: T cell engager at the new target through lead generation stage, GITR-mediated T cell dynamics, species translation to make human predictions, and mechanistic predictions in checkpoint inhibitors.

"We are excited to present at the Next-Gen Immuno-Oncology Congress for the first time this year," said John Burke, PhD, Co-Founder, President and CEO of Applied BioMath. "This presentation establishes how developing and interrogating a systems pharmacology model earlier in the project helps project teams make informed decisions that can provide better mechanistic prediction into humans and help identify the winners, screen for the best candidates possible, and accelerate the winner into the clinic."

Applied BioMath employs a rigorous fit-for-purpose model development process which quantitatively integrates knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms.  Their approach employs proprietary algorithms and software that were designed specifically for systems pharmacology model development, simulation, and analysis.

For more information about Applied BioMath's capabilities, please visit https://www.appliedbiomath.com/applying-scientific-expertise/capabilities.

About Applied BioMath

Founded in 2013, Applied BioMath's mission is to revolutionize drug invention. Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.

Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com